Vermont Law Review — The Quota Crisis: Vyvanse, Adderall, and the Regulation That Limits Access

Summary

Vermont Law Review student-edited legal journal piece (October 2025) analyzing the DEA’s Aggregate Production Quota (APQ) regulatory framework and its structural role in the ongoing ADHD stimulant shortage. Provides the legal-academic framing missing from news coverage: cites specific CSA provisions (21 U.S.C. §§ 826, 823; 21 CFR § 1303), documents the 2018 DEA rule change that elevated diversion-prevention over access, and proposes three specific statutory reforms. Core argument: quotas are a “crass instrument” for stimulant misuse, and current CSA implementation prioritizes diversion control over legitimate medical access, violating the statute’s own balancing requirement.

Key Points

• Statutory framework:
  • 21 U.S.C. § 826 — requires DEA to set aggregate production quotas annually for Schedule I and II substances
  • 21 U.S.C. § 812 — Schedule classification
  • 21 CFR § 1303.03 (2023) — manufacturer-specific and procurement quota regulations
  • 21 CFR § 1303.11(b) — dosage-form measurement regulations
  • 21 U.S.C. § 356c — drug shortage statute (FDA authority)
  • 21 U.S.C. § 823 — DEA registration authority
• Statutory balance language: “The CSA directs the Attorney General to set quotas at levels ‘necessary to meet the estimated medical, scientific, and research needs of the United States.‘”
• The 2018 framework shift: “In 2018, the DEA revised its framework to emphasize diversion risks in quota setting, increasing its discretion to limit supply further.” (Citing 83 Fed. Reg. 32784, 32790, July 16, 2018)
• Case of the 2024 Vyvanse adjustment: “By September [2024], the APQ for lisdexamfetamine (Vyvanse) and d-amphetamine (for conversion) increased after the FDA formally requested an increase based on shortage data.” Author comments: “This incident demonstrates that the safety valve can function — but only after supply stress has persisted long enough to trigger pressure from patients, public health officials, and congressional oversight measures.”
• Shortage timeline: FDA first acknowledged Adderall shortage October 2022; constraints “spilled into other stimulants” especially once Vyvanse generics launched in 2023
• Congressional oversight: “In 2023, [Congress] outlined the federal levers for addressing Adderall shortages. Additionally, in 2024, Congress pressed the DEA on how it weighs medical need against diversion in its quota decisions.”
• The methodology transparency gap: “Neither DEA’s annual APQ notices nor individual-quota adjudications consistently disclose how prescribing trends, shortage data, and inventory levels are weighted.”
• Author’s critical framing: “DEA policy gives diversion priority over accessibility. Post-opioid crisis rules elevated ‘potential for diversion’ in quota setting. That makes sense for harm reduction, but stimulants are not opioids, and shortages impose their own health risks, such as school and work impairment, driving hazards for narcolepsy patients, and mental-health setbacks for those dealing with binge eating disorder.”

Three Specific Statutory Reform Proposals

1. Make medical-need findings explicit and data-driven: Congress should amend 21 U.S.C. § 826 to require the DEA to use and publish current-year demand inputs from the FDA (utilization, prescriptions filled, new approvals, pediatric use), along with inventory and backorder metrics.

2. Formalize the FDA’s role in stimulant quotas: Congress can give the FDA a consultation trigger for Schedule II stimulant APQs and individual quotas, especially during declared shortages under 21 U.S.C. § 356c. Author notes the 2024 lisdexamfetamine order already reflects de facto reliance on FDA shortage determinations — “the law should make that coordination proactive, not emergency-only.”

3. Improve oversight and public accountability: Congress should continue bipartisan oversight, requesting methodology, inventories, and allocation rationales to verify whether rising diagnoses and legitimate prescribing are reflected in quota levels.

• On targeted alternatives: “Targeted tools such as prescription drug monitoring programs (PDMPs), telehealth prescribing standards, and audits of high-risk prescribers directly mitigate misuse while keeping legitimate patients supplied.”

Newsletter Angles

• The legal-academic backbone for any chokepoint piece: Everything Reason reported about Ascent is here with the statutory citations. A Substack piece on chokepoint control can reference the Vermont Law Review analysis as the scholarly treatment without getting into statutory weeds.
• The 2018 framework shift is the regulatory pivot: When the DEA “revised its framework to emphasize diversion risks in quota setting,” it was during peak opioid crisis response. But stimulants aren’t opioids, and the framework change applied to them anyway. That’s the specific date for when the chokepoint tightened.
• “Safety valve functions only after supply stress persists long enough” is the money quote: This is the structural description of the chokepoint mechanism. The DEA will eventually adjust quotas, but only under sufficient political pressure. That’s not regulation — that’s gatekeeping calibrated to public attention, not medical need.
• The reform proposals are actually writeable: Unlike vague “the system is broken” complaints, the Vermont Law Review proposes three specific statutory amendments. That gives a newsletter piece a concrete policy angle: here’s what Congress could do tomorrow that would fix this.

Entities Mentioned

• Drug Enforcement Administration (DEA) — primary regulator
• Food and Drug Administration (FDA) — interagency counterpart with shortage declaration authority
• Department of Health and Human Services (HHS) — documented record-level shortages
• U.S. Congress — oversight body with reform authority
• House Committee on Oversight and Accountability — letter to DEA Administrator Anne Milgram
• Anne Milgram — DEA Administrator referenced in congressional letter
• Vermont Law Review — publisher

Concepts Mentioned

• DEA Aggregate Production Quotas
• ADHD Medication Shortage
• Controlled Substances Act — 21 U.S.C. § 826 et seq.
• Diversion vs. Access Balance — the statutory tension
• Drug Shortage Statute — 21 U.S.C. § 356c
• Chokepoint Control — the structural theory this case instantiates
• Prescription Drug Monitoring Programs (PDMPs) — proposed alternative
• Regulatory Weaponization — implicit; this is what the 2018 framework shift enabled

Quotes

“While manufacturing difficulties and swings in demand play a part, the core driver is pure regulatory red tape: the Drug Enforcement Administration’s (DEA) annual production quotas for Schedule II stimulants. These quotas, designed to prevent diversion, now function as a restriction to accessibility.”

“This incident demonstrates that the safety valve can function — but only after supply stress has persisted long enough to trigger pressure from patients, public health officials, and congressional oversight measures.”

“DEA policy gives diversion priority over accessibility. Post-opioid crisis rules elevated ‘potential for diversion’ in quota setting. That makes sense for harm reduction, but stimulants are not opioids.”

Notes

Student-edited law review, but the piece is legally rigorous and well-cited. Not the most authoritative legal commentary (that would be a bigger-name journal), but sufficient for citation in a newsletter context. The reform proposals are the most useful element for editorial purposes — they give a piece a concrete policy frame that’s unusual in DEA quota coverage. The 2018 framework shift date (83 Fed. Reg. 32784) is specific and citable. Pair with the Reason piece on Ascent and the Federal Register 2026 APQ for a complete picture: statute → 2018 shift → case study → current quotas.